University of Virginia, Charlottesville, VA, USA
Men-Tsee-Khang, Tibetan Medical & Astro Institute, Dharamsala, India Kachupa is similar to Bachelor of Science in Medicine (BS), and Menrampa is similar to Doctor of Medicine (MD).
Integr Cancer Ther. 2014 Nov;13(6):502-12. doi: 10.1177/1534735414549624. Epub 2014 Sep 10.
Tibetan medicine (TM) is a whole systems medical approach that has had growing interest in the West. However, minimal research, particularly with cancer, has been conducted. The purpose of this article is to provide an overview of TM and describe a clinical case review study to obtain preliminary evidence of TM's safety and effect on patients treated for cancer or hematologic disorders.
A retrospective case review was conducted in India and cases met the following inclusion criteria: (a) confirmed diagnosis of cancer or hematologic disorder by standard Western biomedical diagnostic tests, (b) either treated exclusively with TM or received insufficient Western treatment followed by TM and (c) were in remission or had stable disease at least 2 years after start of TM.
Three cases were identified, 1 solid tumor and 2 hematologic diseases: Case 1--poorly to moderately differentiated adenocarcinoma of the stomach, positive lymph nodes and mucosal infiltration, with clear scans and excellent quality of life 29 months later ; Case 2--chronic myelogenous leukemia with normalization of hematologic labs within 3 months of starting TM and stable 4 years later; and Case 3--red cell aplasia improved significantly and reversed dependence on blood transfusions with TM. None of the cases experienced demonstrable adverse effects from TM.
This limited case review found TM to be safe and have positive effects on quality of life and disease regression and remission in patients with cancer and blood disorders. Further exploration and investigation using rigorous methods is warranted.
藏医（TM）是一种整体医学方法，在西方越来越受到关注。然而，针对癌症的研究很少。本文的目的是提供 TM 的概述，并描述一项临床病例回顾研究，以获得 TM 治疗癌症或血液疾病患者的安全性和疗效的初步证据。
在印度进行了回顾性病例回顾，病例符合以下纳入标准：（a）通过标准的西方生物医学诊断测试确认癌症或血液疾病的诊断，（b）仅接受 TM 治疗或接受不足的西方治疗后接受 TM 治疗，以及（c）在开始 TM 后至少 2 年处于缓解或稳定疾病状态。
确定了 3 例病例，1 例为实体瘤，2 例为血液疾病：病例 1-胃中分化不良至中度腺癌，阳性淋巴结和黏膜浸润，扫描清晰，生活质量良好 29 个月后；病例 2-慢性髓性白血病，开始接受 TM 治疗后 3 个月内血液实验室指标正常，4 年后稳定；病例 3-红细胞再生障碍症显著改善，对 TM 的输血依赖逆转。TM 治疗未导致任何病例出现明显不良反应。
这项有限的病例回顾发现，TM 对癌症和血液疾病患者的生活质量和疾病缓解有积极影响，且安全。需要使用严格的方法进一步探索和研究。
